Month: July 2018

CAR-T: The Future Roadmap of The USD 15 Billion+ Opportunity

Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Amidst the current initiatives to develop more targeted anti-cancer therapies,

Cell Therapy Manufacturing: The USD 8 Billion+ Growth Opportunity

Cell-based therapies have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also